A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia

NCT03195491 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer
Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL: Nivolumab

Sponsor

Bristol-Myers Squibb